{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:57:26Z","timestamp":1790629046427,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018M3A9H1078335"],"award-info":[{"award-number":["NRF-2018M3A9H1078335"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurofibromatosis type 1 (NF1) is a common human genetic disease with age-dependent phenotype progression. The overview of clinical and radiological findings evaluated by whole-body magnetic resonance imaging (WBMRI) in NF1 patients\u2009&lt;\u20093\u00a0years old assessed with a genetic contribution to disease progression is presented herein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study included 70 clinically or genetically diagnosed NF1 patients who received WBMRI before 3\u00a0years old. Clinical, genetic, and radiologic features were collected by retrospective chart review. In NF1\n                      <jats:sup>+<\/jats:sup>\n                      , widely spread diffuse cutaneous neurofibromas, developmental delay, autism, seizure, cardiac abnormalities, hearing defect, optic pathway glioma, severe plexiform neurofibromas (&gt;\u20093\u00a0cm in diameter, disfigurement, accompanying pain, bony destruction, or located para-aortic area), brain tumors, nerve root tumors, malignant peripheral nerve sheath tumors, moyamoya disease, and bony dysplasia were included.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The age at WBMRI was 1.6\u2009\u00b1\u20090.7\u00a0years old, and\n                      <jats:italic>NF1<\/jats:italic>\n                      mutations were found in 66 patients (94.3%). Focal areas of signal intensity (FASI) were the most common WBMRI finding (66.1%), followed by optic pathway glioma (15.7%), spine dural ectasia (12.9%), and plexiform neurofibromas (10.0%). Plexiform neurofibromas and NF1\n                      <jats:sup>+<\/jats:sup>\n                      were more prevalent in familial case (28.7% vs 5.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.030; 71.4% vs 30.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011). Follow-up WBMRI was conducted in 42 patients (23 girls and 19 boys) after 1.21\u2009\u00b1\u20090.50\u00a0years. FASI and radiologic progression were more frequent in patients with mutations involving GTPase activating protein-related domain (77.8% vs 52.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047; 46.2% vs 7.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      WBMRI provides important information for the clinical care for young pediatric NF1 patients. As NF1 progresses in even these young patients, and is related to family history and the affected\n                      <jats:italic>NF1<\/jats:italic>\n                      domains, serial evaluation with WBMRI should be assessed based on the clinical and genetic features for the patients\u2019 best care.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-022-02174-3","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T07:03:03Z","timestamp":1643439783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Whole-body MRI evaluation in neurofibromatosis type 1 patients younger than 3 years old and the genetic contribution to disease progression"],"prefix":"10.1186","volume":"17","author":[{"given":"Eungu","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Myung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunha","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JunYoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Wook","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Mang","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9709-2631","authenticated-orcid":false,"given":"Beom Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"issue":"1","key":"2174_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","volume":"89","author":"JM Friedman","year":"1999","unstructured":"Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet. 1999;89(1):1\u20136.","journal-title":"Am J Med Genet"},{"issue":"2","key":"2174_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152a","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152a(2):327\u201332.","journal-title":"Am J Med Genet A"},{"issue":"8","key":"2174_CR3","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1212\/WNL.54.8.1646","volume":"54","author":"K DeBella","year":"2000","unstructured":"DeBella K, Poskitt K, Szudek J, Friedman JM. Use of \u201cunidentified bright objects\u201d on MRI for diagnosis of neurofibromatosis 1 in children. Neurology. 2000;54(8):1646\u201351.","journal-title":"Neurology"},{"issue":"4","key":"2174_CR4","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/0888-7543(91)90017-9","volume":"11","author":"DA Marchuk","year":"1991","unstructured":"Marchuk DA, Saulino AM, Tavakkol R, Swaroop M, Wallace MR, Andersen LB, et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics. 1991;11(4):931\u201340.","journal-title":"Genomics"},{"issue":"6551","key":"2174_CR5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/377695a0","volume":"377","author":"M Henkemeyer","year":"1995","unstructured":"Henkemeyer M, Rossi DJ, Holmyard DP, Puri MC, Mbamalu G, Harpal K, et al. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature. 1995;377(6551):695\u2013701.","journal-title":"Nature"},{"issue":"6290","key":"2174_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/347291a0","volume":"347","author":"AM Buchberg","year":"1990","unstructured":"Buchberg AM, Cleveland LS, Jenkins NA, Copeland NG. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature. 1990;347(6290):291\u20134.","journal-title":"Nature"},{"issue":"1","key":"2174_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0004.2006.00639.x","volume":"70","author":"AB Trov\u00f3-Marqui","year":"2006","unstructured":"Trov\u00f3-Marqui AB, Tajara EH. Neurofibromin: a general outlook. Clin Genet. 2006;70(1):1\u201313.","journal-title":"Clin Genet"},{"issue":"11","key":"2174_CR8","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.3390\/cells9112365","volume":"9","author":"M Bergoug","year":"2020","unstructured":"Bergoug M, Doudeau M, Godin F, Mosrin C, Vall\u00e9e B, B\u00e9n\u00e9detti H. Neurofibromin structure, functions and regulation. Cells. 2020;9(11):2365.","journal-title":"Cells"},{"issue":"2","key":"2174_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/sj.bjc.6603227","volume":"95","author":"L Walker","year":"2006","unstructured":"Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer. 2006;95(2):233\u20138.","journal-title":"Br J Cancer"},{"issue":"17","key":"2174_CR10","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","volume":"34","author":"E Uusitalo","year":"2016","unstructured":"Uusitalo E, Rantanen M, Kallionp\u00e4\u00e4 RA, P\u00f6yh\u00f6nen M, Lepp\u00e4virta J, Yl\u00e4-Outinen H, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34(17):1978\u201386.","journal-title":"J Clin Oncol"},{"issue":"7 Suppl 1","key":"2174_CR11","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1212\/WNL.0000000000002929","volume":"87","author":"S Ahlawat","year":"2016","unstructured":"Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, et al. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology. 2016;87(7 Suppl 1):S31\u20139.","journal-title":"Neurology"},{"key":"2174_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01170-5","author":"E Legius","year":"2021","unstructured":"Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021. https:\/\/doi.org\/10.1038\/s41436-021-01170-5.","journal-title":"Genet Med"},{"key":"2174_CR13","unstructured":"National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13\u201315, 1987. Neurofibromatosis 1988, 1(3):172\u20138."},{"issue":"8","key":"2174_CR14","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","volume":"13","author":"AC Hirbe","year":"2014","unstructured":"Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834\u201343.","journal-title":"Lancet Neurol"},{"issue":"9","key":"2174_CR15","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1002\/ajmg.a.35535","volume":"158a","author":"MT Acosta","year":"2012","unstructured":"Acosta MT, Bearden CE, Castellanos FX, Cutting L, Elgersma Y, Gioia G, et al. The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. Am J Med Genet A. 2012;158a(9):2225\u201332.","journal-title":"Am J Med Genet A"},{"issue":"16","key":"2174_CR16","doi-asserted-by":"publisher","first-page":"e136262","DOI":"10.1172\/jci.insight.136262","volume":"5","author":"MM Tabata","year":"2020","unstructured":"Tabata MM, Li S, Knight P, Bakker A, Sarin KY. Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry. JCI Insight. 2020;5(16):e136262.","journal-title":"JCI Insight"},{"issue":"2","key":"2174_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s10038-019-0695-0","volume":"65","author":"E Kang","year":"2020","unstructured":"Kang E, Kim YM, Seo GH, Oh A, Yoon HM, Ra YS, et al. Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types. J Hum Genet. 2020;65(2):79\u201389.","journal-title":"J Hum Genet"},{"issue":"5","key":"2174_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3345\/kjp.2018.61.5.135","volume":"61","author":"JH Kim","year":"2018","unstructured":"Kim JH, Yun S, Hwang SS, Shim JO, Chae HW, Lee YJ, et al. The 2017 Korean National Growth Charts for children and adolescents: development, improvement, and prospects. Korean J Pediatr. 2018;61(5):135\u201349.","journal-title":"Korean J Pediatr"},{"issue":"1","key":"2174_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1589\/jpts.27.269","volume":"27","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Shin JI. A study of the correlation between BSID-III and KICDT for children with developmental delay. J Phys Ther Sci. 2015;27(1):269\u201371.","journal-title":"J Phys Ther Sci"},{"key":"2174_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/978-3-642-32864-0_20","volume-title":"Neurofibromatosis type 1: molecular and cellular biology","author":"K Scheffzek","year":"2012","unstructured":"Scheffzek K, Welti S. Neurofibromin: protein domains and functional characteristics. In: Upadhyaya M, Cooper DN, editors. Neurofibromatosis type 1: molecular and cellular biology. Berlin: Springer; 2012. p. 305\u201326. https:\/\/doi.org\/10.1007\/978-3-642-32864-0_20."},{"issue":"Suppl 2","key":"2174_CR21","first-page":"S3","volume":"44","author":"MT Acosta","year":"2007","unstructured":"Acosta MT. The neurobiology of learning difficulties: neurofibromatosis type 1 as a model for researching and treating learning disorders. Rev Neurol. 2007;44(Suppl 2):S3-8.","journal-title":"Rev Neurol"},{"issue":"4","key":"2174_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S1474-4422(07)70075-3","volume":"6","author":"RE Ferner","year":"2007","unstructured":"Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol. 2007;6(4):340\u201351.","journal-title":"Lancet Neurol"},{"issue":"s01","key":"2174_CR23","first-page":"S59","volume":"64","author":"JJ Garcia-Penas","year":"2017","unstructured":"Garcia-Penas JJ. Learning disorders in neurofibromatosis type 1. Rev Neurol. 2017;64(s01):S59-s63.","journal-title":"Rev Neurol"},{"issue":"1","key":"2174_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0022-3476(94)70122-9","volume":"125","author":"R Listernick","year":"1994","unstructured":"Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr. 1994;125(1):63\u20136.","journal-title":"J Pediatr"},{"issue":"5","key":"2174_CR25","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S0022-3476(95)70159-1","volume":"127","author":"R Listernick","year":"1995","unstructured":"Listernick R, Darling C, Greenwald M, Strauss L, Charrow J. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr. 1995;127(5):718\u201322.","journal-title":"J Pediatr"},{"issue":"3","key":"2174_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/ajmg.a.20650","volume":"127a","author":"MA Blazo","year":"2004","unstructured":"Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE. Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1. Am J Med Genet A. 2004;127a(3):224\u20139.","journal-title":"Am J Med Genet A"},{"key":"2174_CR27","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-0660","author":"DT Miller","year":"2019","unstructured":"Miller DT, Freedenberg D, Schorry E, Ullrich NJ, Viskochil D, Korf BR. Health supervision for children with neurofibromatosis type 1. Pediatrics. 2019. https:\/\/doi.org\/10.1542\/peds.2019-0660.","journal-title":"Pediatrics"},{"issue":"1","key":"2174_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13023-020-1310-3","volume":"15","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Servy A, Valeyrie-Allanore L, Ferkal S, Combemale P, Wolkenstein P. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020;15(1):37.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2174_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3345\/cep.2020.00871","volume":"64","author":"E Kang","year":"2021","unstructured":"Kang E, Yoon HM, Lee BH. Neurofibromatosis type I: points to be considered by general pediatricians. Clin Exp Pediatr. 2021;64(4):149\u201356.","journal-title":"Clin Exp Pediatr"},{"issue":"1","key":"2174_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W","volume":"89","author":"BR Korf","year":"1999","unstructured":"Korf BR. Plexiform neurofibromas. Am J Med Genet. 1999;89(1):31\u20137.","journal-title":"Am J Med Genet"},{"issue":"2","key":"2174_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2008.061051","volume":"46","author":"T Tucker","year":"2009","unstructured":"Tucker T, Friedman JM, Friedrich RE, Wenzel R, F\u00fcnsterer C, Mautner VF. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. J Med Genet. 2009;46(2):81\u20135.","journal-title":"J Med Genet"},{"issue":"3","key":"2174_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/BPO.0b013e31820cad77","volume":"31","author":"F Canavese","year":"2011","unstructured":"Canavese F, Krajbich JI. Resection of plexiform neurofibromas in children with neurofibromatosis type 1. J Pediatr Orthop. 2011;31(3):303\u201311.","journal-title":"J Pediatr Orthop"},{"issue":"15","key":"2174_CR33","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430\u201342.","journal-title":"N Engl J Med"},{"issue":"4","key":"2174_CR34","doi-asserted-by":"publisher","first-page":"e35711","DOI":"10.1371\/journal.pone.0035711","volume":"7","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S, et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS ONE. 2012;7(4):e35711.","journal-title":"PLoS ONE"},{"key":"2174_CR35","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"2174_CR36","doi-asserted-by":"publisher","first-page":"E1506","DOI":"10.1002\/humu.21271","volume":"31","author":"E Pasmant","year":"2010","unstructured":"Pasmant E, Sabbagh A, Spurlock G, Laurendeau I, Grillo E, Hamel MJ, et al. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat. 2010;31(6):E1506\u201318.","journal-title":"Hum Mutat"},{"issue":"9","key":"2174_CR37","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/jmg.2009.075937","volume":"47","author":"VF Mautner","year":"2010","unstructured":"Mautner VF, Kluwe L, Friedrich RE, Roehl AC, Bammert S, Hogel J, et al. Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions. J Med Genet. 2010;47(9):623\u201330.","journal-title":"J Med Genet"},{"issue":"1","key":"2174_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ajhg.2017.12.001","volume":"102","author":"M Koczkowska","year":"2018","unstructured":"Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, et al. Genotype-Phenotype Correlation in NF1: Evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844\u2013848. Am J Hum Genet. 2018;102(1):69\u201387.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2174_CR39","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1086\/510781","volume":"80","author":"M Upadhyaya","year":"2007","unstructured":"Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970\u20132972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet. 2007;80(1):140\u201351.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2174_CR40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/humu.23929","volume":"41","author":"M Koczkowska","year":"2020","unstructured":"Koczkowska M, Callens T, Chen Y, Gomes A, Hicks AD, Sharp A, et al. Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. Hum Mutat. 2020;41(1):299\u2013315.","journal-title":"Hum Mutat"},{"issue":"8","key":"2174_CR41","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/ejhg.2014.243","volume":"23","author":"V Pinna","year":"2015","unstructured":"Pinna V, Lanari V, Daniele P, Consoli F, Agolini E, Margiotti K, et al. p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas. Eur J Hum Genet. 2015;23(8):1068\u201371.","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"2174_CR42","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0092-8674(90)90151-4","volume":"63","author":"R Ballester","year":"1990","unstructured":"Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 1990;63(4):851\u20139.","journal-title":"Cell"},{"issue":"23","key":"2174_CR43","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1523\/JNEUROSCI.4693-04.2005","volume":"25","author":"B Dasgupta","year":"2005","unstructured":"Dasgupta B, Gutmann DH. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci. 2005;25(23):5584\u201394.","journal-title":"J Neurosci"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02174-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02174-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02174-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T07:09:54Z","timestamp":1643440194000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02174-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2174"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02174-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-863524\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"31 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board at the Asan Medical Center (IRB number 2021-1084), and appropriate written informed consent was obtained from the patient\u2019s parents for <i>NF1<\/i> gene testing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}